Alpha 2.0
Login Register
» Articles » PMID: 38551680

Origin and Significance of Leucine-rich Glioma-inactivated 1 Antibodies in Cerebrospinal Fluid

Overview
Journal Neurol Sci
Specialty Neurology
Date 2024 Mar 29
PMID 38551680
Authors
Fang Zhang
Hong Zhou
Yujie Yi
Na Li
Miaomiao Liu
Huijun Shen
Yingshi Guo
Jie Wang
Affiliations
Soon will be listed here.
Abstract

Background: Whether antibodies against leucine-rich glioma-inactivated 1 (LGI1-Abs) in cerebrospinal fluid (CSF) are partially transferred from serum and the impact of CSF-LGI1-Ab positivity on clinical features and prognosis are unclear. Therefore, we aim to investigate the differences in serum titers, clinical features, and outcomes between LGI1-Ab CSF-positive and LGI1-Ab CSF-negative patients.

Methods: Retrospective analysis of serum titers and clinical features according to CSF LGI1-Ab status. In addition, univariate and multivariate logistic regression were performed to identify predictors of worse outcomes.

Results: A total of 60 patients with anti-LGI1 encephalitis and positive serum LGI1-Abs were identified, of whom 8 (13.3%) patients were excluded due to the absence of CSF LGI1-Ab testing. Among the remaining 52 patients, 33 (63.5%) were positive for LGI1-Abs in CSF. CSF-positive patients were more likely to have high serum titers (≥ 1:100) than CSF-negative patients (p = 0.003), and Spearman's correlation analysis showed a positive correlation between CSF and serum titers in CSF-positive patients (r = 0.405, p = 0.019). Psychiatric symptoms and hyponatremia were more frequent in CSF-positive patients (p < 0.05). Both univariate and multivariate logistic regression analyses showed that CSF LGI1-Ab positivity and delayed immunotherapy are independent risk factors for incomplete recovery (modified Rankin Scale (mRS) > 0 at last follow-up).

Conclusions: LGI1-Ab CSF-positive patients have higher serum titers, and their CSF titers are positively correlated with serum titers, indicating a possible peripheral origin of CSF LGI1-Abs. CSF-positive patients more often present with psychiatric symptoms, hyponatremia, and worse outcomes, suggesting more severe neuronal damage.

References
1.
Graus F, Titulaer M, Balu R, Benseler S, Bien C, Cellucci T . A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016; 15(4):391-404. PMC: 5066574. DOI: 10.1016/S1474-4422(15)00401-9. View
2.
Zuliani L, Marangoni S, De Gaspari P, Rosellini I, Nosadini M, Fleming J . Epidemiology of neuronal surface antibody-mediated autoimmune encephalitis and antibody-based diagnostics. J Neuroimmunol. 2021; 357:577598. DOI: 10.1016/j.jneuroim.2021.577598. View
3.
van Sonderen A, Thijs R, Coenders E, Jiskoot L, Sanchez E, de Bruijn M . Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology. 2016; 87(14):1449-1456. DOI: 10.1212/WNL.0000000000003173. View
4.
Ramberger M, Berretta A, Tan J, Sun B, Michael S, Yeo T . Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms. Brain. 2020; 143(6):1731-1745. PMC: 7296845. DOI: 10.1093/brain/awaa104. View
5.
Cui L, Boltze J, Zhang Y . Positive LGI1 Antibodies in CSF and Relapse Relate to Worse Outcome in Anti-LGI1 Encephalitis. Front Immunol. 2022; 12:772096. PMC: 8718904. DOI: 10.3389/fimmu.2021.772096. View